Black Rock Inc. Immunic, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Immunic, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 679,343 shares of IMUX stock, worth $631,788. This represents 0.0% of its overall portfolio holdings.

Number of Shares

679,343

Previous 661,254 2.74%

Holding current value

$631,788

Previous $872,000 13.53%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$0.98 - $1.44 $17,727 - $26,048	18,089 Added 2.74%	679,343 $754,000
Q1 2024 May 10, 2024	BUY	$1.14 - $1.53 $341,005 - $457,665	299,128 Added 82.6%	661,254 $872,000
Q4 2023 Feb 13, 2024	BUY	$0.97 - $1.6 $5,157 - $8,507	5,317 Added 1.49%	362,126 $543,000
Q3 2023 Nov 13, 2023	SELL	$1.35 - $2.87 $27,936 - $59,391	-20,694 Reduced 5.48%	356,809 $524,000
Q2 2023 Aug 11, 2023	BUY	$1.33 - $2.51 $12,051 - $22,743	9,061 Added 2.46%	377,503 $947,000
Q1 2023 May 12, 2023	BUY	$1.35 - $2.87 $2,299 - $4,887	1,703 Added 0.46%	368,442 $548,000
Q4 2022 Feb 13, 2023	SELL	$1.13 - $10.8 $112,771 - $1.08 Million	-99,798 Reduced 21.39%	366,739 $513,000
Q3 2022 Nov 14, 2022	SELL	$3.0 - $5.49 $15,342 - $28,075	-5,114 Reduced 1.08%	466,537 $1.48 Million
Q2 2022 Aug 12, 2022	SELL	$3.13 - $12.25 $2.64 Million - $10.3 Million	-842,833 Reduced 64.12%	471,651 $1.64 Million
Q1 2022 May 12, 2022	BUY	$9.54 - $14.26 $111,694 - $166,956	11,708 Added 0.9%	1,314,484 $14.9 Million
Q4 2021 Feb 10, 2022	BUY	$7.34 - $10.25 $378,971 - $529,217	51,631 Added 4.13%	1,302,776 $12.5 Million
Q3 2021 Nov 09, 2021	BUY	$8.05 - $13.29 $1.01 Million - $1.66 Million	124,852 Added 11.09%	1,251,145 $11.1 Million
Q2 2021 Aug 11, 2021	BUY	$11.76 - $16.85 $13.2 Million - $19 Million	1,126,293 New	1,126,293 $13.8 Million

Others Institutions Holding IMUX

# of Institutions

Shares Held

46.9M

Call Options Held

1.14M

Put Options Held

130K

View Full List

About IMMUNIC, INC.

Ticker IMUX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,565,000
Market Cap $28.4M
Description
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...

More about IMUX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account